ClinicalTrials.gg
Active, not recruitingNCT06092879ASSURE-3Updated May 29, 2026

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

An observational study in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 52 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
201
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis — 9 open to participants now, 13 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Novartis.

Enrollment
13th of 19
201 · median 400
Started
2024
with 3 others
Observational
19 of 92
6 open now
Primary completion
2026-12
later than 2 of 12 live
Registered
78th of 92
by date

Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 13th largest by enrollment of the 19 observational ones that give a count, is one of 4 that started in 2024, is one of 19 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 78th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 107 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

9 of the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 77 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 47 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to enhance the knowledge on asciminib treatment in a broader and real-life population by collecting additional data to characterize the treatment patterns of patients treated with asciminib, with a primary objective represented by maintenance on treatment at 12 months.

Read the detailed description

The ASSURE-3 study is a national, multicentric, non-interventional, prospective study in real-life conditions with primary data collection in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more Tyrosine Kinase Inhibitors (TKIs). It will be conducted in France with hematologists, onco-hematologists, physicians with documented involvement in managing Ph+ CML-CP patients in routine practice, practicing in public or private health care institutions. Each patient will be followed during 15 months at M0, M1 and then every 3 months (rhythm of visits according to the routine clinical care), or until premature discontinuation of asciminib treatment.

Historical data will be abstracted retrospectively by the participating physicians from patient files, to collect information using an electronic case report form (eCRF). Primary data will be collected during inclusion and follow-up visits

03

Conditions studied

  • Chronic Myeloid Leukemia

Keywords

  • Chronic myeloid leukemia
  • CML
  • asciminib
  • France
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged ≥ 18 years at inclusion,
  2. Patient with Ph+ CML-CP previously treated with two or more TKIs,
  3. Patient for whom a decision has been taken by the treating physician (investigator) to initiate treatment with asciminib according to his own practice, the drug label / Summary of Product Characteristics (SmPC), and regardless of study participation,
  4. Patient having given their non objection to participate to the study

Exclusion criteria

Exclusion Criteria:

  1. Patient with CML in accelerated phase (AP) or blastic phase (BP) at enrolment,
  2. Patient with known history of T315I mutation,
  3. Patient who previously received asciminib treatment,
  4. Patient currently participating to an interventional clinical trial,
  5. Patient with known to asciminib according to the SmPC.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
201 participants (actual)
Patient registry
No

Groups and cohorts

  • Asciminib

    Adult patients with Ph+ CML-CP previously treated with two or more tyrosine kinase inhibitors

    Other: Asciminib

Interventions

  • OtherAsciminib

    There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled

    Also known as: Scemblix

06

What researchers measure

Primary outcomes

  1. Proportion of patients remaining on asciminib at 12 months

    Proportion of patients remaining on asciminib treatment at 12 months to be provided

    Time frame: Month 12

Secondary outcomes

  1. Proportion of patients in major molecular response (MMR) - for patients not in MMR at treatment initiation

    Molecular response to treatment: Response to treatment (MMR, BCR::ABL1 ≤ 0.1% on the International Scale, IS) at 12 months (+/- 1 month) for patients not in MMR at treatment initiation

    Time frame: 12 months

  2. Proportion of patients in MMR - for patients in MMR at treatment initiation

    Molecular response to treatment: Maintenance of molecular response (MMR, BCR::ABL1 ≤ 0.1% on the International Scale, IS) at 12 months (+/- 1 month) for patients in MMR at treatment initiation

    Time frame: 12 months

  3. Proportion of patients in MR2, MMR, MR4.0, MR4.5, uMR4.5 - for all patients

    Molecular response to treatment: Kinetics of response: MR2, MMR, MR4.0, MR4.5, undetectable MR4.5 for all patients. MR2, MR4, MR4.5 are defined as the transcript ratio of BCR-ABL1/ABL1 being 1% or less, 0.01% or less and 0.0032% or less respectively

    Time frame: 3 months, 6 months, 9 months, 12 months and 15 months

  4. BCR::ABL1 on the International Scale (IS) kinetics along treatment - for all patients

    Kinetics of response: BCR::ABL1 on the International Scale (IS) for all patients

    Time frame: 15 months

  5. Time to MMR from the index date - for patients not in MMR at treatment initiation

    Kinetics of response: Time to MMR for patients not in MMR at treatment initiation

    Time frame: Up to 15 months

  6. Time from the first MMR to the first loss of MMR - for patients not in MMR at treatment initiation

    Molecular response to treatment: Duration of MMR for patients not in MMR at treatment initiation

    Time frame: Up to 15 months

  7. Event-Free Surviva (EFS)

    EFS: time from index date to occurrence of one the events listed among variables: * lack of efficacy, i.e., BRC::ABL1\>1% or loss of CCyR if assessed * disease progression (CML-AP/BP, CML death) * death from any cause * definitive treatment discontinuation due to any reason

    Time frame: Up to 15 months

  8. Progression-Free Survival (PFS)

    PFS: time from index date to occurrence of one of the progression markers listed among variables: * disease progression (CML-AP/BP, CML death), * death from any cause, * definitive treatment discontinuation due to any reason

    Time frame: Up to 15 months

  9. Comorbidity profile

    Charlson comorbidity index (CCI) at index date

    Time frame: Baseline

  10. Disease characteristics

    Disease characteristics to be provided

    Time frame: Baseline

  11. History of TKI treatment

    History of TKI treatment to be provided

    Time frame: Baseline

  12. Management of patients in real-life

    Concomitant medications

    Time frame: 15 months

  13. Exposure patterns to asciminib

    Exposure patterns to be provided

    Time frame: 15 months

  14. EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30)

    The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status/ QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

    Time frame: Baseline, 3months, 6months, 9months, 12months, 15months

  15. EORTC QLQ-CML24 questionnaire

    The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML 24 is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in satisfaction with social life domain indicates a higher level of satisfaction. A positive change from baseline indicates increasing satisfaction.

    Time frame: Baseline, 3months, 6months, 9months, 12months, 15months

  16. Emergence of mutations

    If available at end of treatment: mutational analysis, methods and results

    Time frame: Up to 15 months

  17. Proportion of patient with an AE described during asciminib treatment among patient reporting the same AE which led to discontinuation with previous TKI treatments

    Cross intolerance with previous TKI treatments

    Time frame: Up to 15 months

07

Study locations

52 sites
  • Novartis Investigative Site
    Angers, France 49933, France
  • Novartis Investigative Site
    Limoges, Haute Vienne 87000, France
  • Novartis Investigative Site
    Saint Priest Jarez, Pays de la Loire Region 42270, France
  • Novartis Investigative Site
    Aix-en-Provence, 13616, France
  • Novartis Investigative Site
    Amiens, 80054, France
  • Novartis Investigative Site
    Antibes, 06600, France
  • Novartis Investigative Site
    Avignon, 84000, France
  • Novartis Investigative Site
    Besançon, 25030, France
  • Novartis Investigative Site
    Bobigny, 93009, France
  • Novartis Investigative Site
    Bordeaux, 33000, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    Brive-la-Gaillarde, 19100, France
  • Novartis Investigative Site
    Caen, 14033, France
  • Novartis Investigative Site
    Cagnes-sur-Mer, 06800, France
  • Novartis Investigative Site
    Cannes, 06414, France
  • Novartis Investigative Site
    Castelnau-le-Lez, 34170, France
  • Novartis Investigative Site
    Cesson-Sévigné, 35576, France
  • Novartis Investigative Site
    Chambéry, 73000, France
  • Novartis Investigative Site
    Clermont-Ferrand, 63003, France
  • Novartis Investigative Site
    Corbeil-Essonnes, 91100, France
  • Novartis Investigative Site
    Dunkirk, 59240, France
  • Novartis Investigative Site
    Essey-lès-Nancy, 54270, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Le Kremlin-Bicêtre, 94275, France
  • Novartis Investigative Site
    Le Mans, 72000, France
  • Novartis Investigative Site
    Lens, 62307, France
  • Novartis Investigative Site
    Libourne, 33505, France
  • Novartis Investigative Site
    Lorient, 56100, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Montpellier, 34070, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Mulhouse, 68070, France
  • Novartis Investigative Site
    Nantes, 44277, France
  • Novartis Investigative Site
    Nevers, 58000, France
  • Novartis Investigative Site
    Nîmes, 30029, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Perpignan, 66046, France
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Quimper, 29000, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Roubaix, 59100, France
  • Novartis Investigative Site
    Strasbourg, 67085, France
  • Novartis Investigative Site
    Tarbes, 65100, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Tours, 37044, France
  • Novartis Investigative Site
    Valence, 26953, France
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
  • Novartis Investigative Site
    Vesoul, 70014, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 23, 2023
StartActual
Mar 6, 2024
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06092879
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Mar 6, 2024
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
May 29, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion